Iovance Biotherapeutics, Inc. (IOVA)
8.01
-0.25
(-3.03%)
USD |
NASDAQ |
Aug 28, 16:00
8.03
+0.02
(+0.25%)
After-Hours: 20:00
Iovance Biotherapeutics Cash from Operations (Quarterly) : -60.84M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -60.84M |
| March 31, 2026 | -72.07M |
| December 31, 2025 | -52.56M |
| September 30, 2025 | -78.70M |
| June 30, 2025 | -67.45M |
| March 31, 2025 | -103.69M |
| December 31, 2024 | -73.30M |
| September 30, 2024 | -58.97M |
| June 30, 2024 | -98.43M |
| March 31, 2024 | -122.28M |
| December 31, 2023 | -83.97M |
| September 30, 2023 | -84.08M |
| June 30, 2023 | -93.95M |
| March 31, 2023 | -99.82M |
| December 31, 2022 | -77.67M |
| September 30, 2022 | -63.65M |
| June 30, 2022 | -77.64M |
| March 31, 2022 | -73.80M |
| December 31, 2021 | -53.85M |
| September 30, 2021 | -57.69M |
| June 30, 2021 | -54.01M |
| March 31, 2021 | -62.39M |
| December 31, 2020 | -62.69M |
| September 30, 2020 | -40.52M |
| June 30, 2020 | -36.64M |
| Date | Value |
|---|---|
| March 31, 2020 | -65.29M |
| December 31, 2019 | -53.82M |
| September 30, 2019 | -42.18M |
| June 30, 2019 | -33.80M |
| March 31, 2019 | -29.09M |
| December 31, 2018 | -31.55M |
| September 30, 2018 | -27.93M |
| June 30, 2018 | -23.92M |
| March 31, 2018 | -17.85M |
| December 31, 2017 | -20.96M |
| September 30, 2017 | -21.45M |
| June 30, 2017 | -17.50M |
| March 31, 2017 | -18.80M |
| December 31, 2016 | -12.16M |
| September 30, 2016 | -12.21M |
| June 30, 2016 | -3.748M |
| March 31, 2016 | -4.552M |
| December 31, 2015 | -6.579M |
| September 30, 2015 | -3.843M |
| June 30, 2015 | -4.500M |
| March 31, 2015 | -3.459M |
| December 31, 2014 | -3.315M |
| September 30, 2014 | -1.729M |
| June 30, 2014 | -1.322M |
| March 31, 2014 | -2.267M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Amgen, Inc. | 4.002B |
| Halozyme Therapeutics, Inc. | 240.89M |
| Neurocrine Biosciences, Inc. | 78.00M |
| AVITA Medical, Inc. | -3.630M |
| Editas Medicine, Inc. | -29.57M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -74.05M |
| Cash from Financing (Quarterly) | 49.29M |
| Free Cash Flow | -296.40M |
| Free Cash Flow Per Share (Quarterly) | -0.1472 |
| Free Cash Flow to Equity (Quarterly) | -64.51M |
| Free Cash Flow to Firm (Quarterly) | -66.28M |
| Free Cash Flow Yield | -9.03% |